Annovis Bio Stock Plummets on $10M Equity Offering

Annovis Bio Stock Declines Sharply After Offering News

Shares of Annovis Bio Inc (NYSE:ANVS) experienced a significant drop of 26.5% on Thursday after the company revealed the pricing of a dilutive equity offering. The biotechnology firm aims to raise approximately $10 million in gross proceeds through this capital raise, which will fund its clinical programs.

Overview of the Offering

The clinical-stage company priced an underwritten offering of 5,263,156 shares of common stock at $1.90 per share. The offering also includes accompanying warrants to purchase up to an additional 5,263,156 shares. Each warrant has an exercise price of $2.50 per share and becomes exercisable six months after issuance.

Impact on the Market

The announcement led to a sharp sell-off, reflecting investor concerns about share dilution. The estimated $10 million in proceeds, before deducting expenses, will support the company's development of its primary drug candidate, buntanetap, for neurodegenerative diseases like Alzheimer's. This figure excludes potential future proceeds from warrant exercises.

Summary

The offering, managed by Canaccord Genuity as the sole bookrunner, is expected to close on or about April 10, 2024. While the capital injection is crucial for Annovis Bio's clinical trials, it has created immediate downward pressure on its stock value due to the dilutive effect.

FAQ

Q: Why did Annovis Bio's stock price fall?
A: The stock fell due to the announcement of a dilutive equity offering, which increases the number of shares outstanding and can reduce the value of existing shares.

Q: How much capital is Annovis Bio raising?
A: The company expects to raise gross proceeds of approximately $10 million before expenses.

Source: Investing.com